@Jrsy Devil's Advocate®: Which I'm not happy about the name of. Unless it comes with little ferrite rods to allow you to build actual bucky ball models with.
The designer could've at least oriented the letters accordingly so that it was akin to a clock, that way, rotating the entire chart would not be necessary. The standard periodic table is not hard to read or navigate. If you need to find anything from Alkali metals to halogens, it's all color coordinated and oriented in the most usable way possible. No thanks.
Having taken way too many Chemistry courses, I'd say this is pretty useless, at leased in my view. Maybe if the groups were better labeled... But the whole "it shows the sizes of the atom" - so does the current table. I thin kit's way less intuitive also, things like electro-negativity look a bit more confusing to figure out (I guess you just need a starting and ending point, but still.)
The regular periodic table gives you an idea of the size of the atoms too. Going from one row - or PERIOD - to another, the size of the atoms increases because you add an electron shell. All he's done is stuck the left and right ends of the standard periodic table together to suggest a nonexistent circularity in properties in each period.
I can't make head nor tail of the relationships this is supposed to imply. Why are the rare earth metals at the end of the period for the first two rows? Why do hydrogen and helium point at the transition metals? How does the atomic number change across the diagram?
@Kaiser-Machead: A friend of mine had a physics teacher who, when he didn't know the answer to a question, would say "because god made it that way." no joke. this was not a religious school.
@Kaiser-Machead: I had a science teacher in high school that berated me in front of the whole class because I made a reference to being able to see the sun and the moon in the sky at the same time. (she swore this was impossible)
Try looking up once in a while stupid bitch.
These seem like cool devices. I'm not clear on the advantage of performing reactions on a chip in the presence of an enzyme. It seems like you could make a library of compounds using combinatorial chemistry and then screen them using enzymes on a chip.
To address the some issues raised below, R+D costs are essentially negligible when bringing a drug to market. More money is spent in marketing a drug before it is even approved by the FDA than is spent on R+D. This chip would be only a tiny part of R+D.
Secondly, the analysis of the reaction products is not that hard. You run the product solution into the mass spec and measure the ratio of reaction substrates to reaction product. The only trick is to develop a valve system that controls the delivery of the reactions to the mass spec.
Third, the big use for these devices is their use in sensors that allow a small amount of sample (like blood) to be tested against a large panel of drugs. It could give you a deep view into a patients metabolic state, for example.
@Nick: mission accomplished:
"hurry up and wait"... Just curious, do you actually know anything about the FDA approval process for new drugs or are you just echoing what you've heard other say?
@Nick: mission accomplished: I'm pretty sure it has much ado with money changing hands.. sorta like how they screwed over a bunch of people by changing the albuterol inhalers so they work crap and cost 3x the price. Tell me there wasn't some profit margin at work there...
"Using microfluidics, the system may dramatically accelerate drug development for cancer and other diseases:"
...to reduce costs for drug companies, so they can get a new set of gold rims on their bentley golf carts.
@lpranal: I would imagine the opposite effect. Lower development costs and research time would enable smaller companies to penetrate (hehe penetrate) the market, driving down profits for large drug companies.
@Hello Mister Walrus: the optimistic part of me wants to believe that, but the bigger drug companies didn't get that way by letting the smaller guys get access to this stuff
@Hello Mister Walrus: Its not as much development costs as it is going through the clinical trials to get a drug FDA approved and actually to market. Hardly anyone besides BigPharma can pay for the phase II/III trials.
@Skeptics: It's reasonable to assume that any reduction in production time and, consequently, costs for producing new drugs would constitute a reduction in barriers to entry in the pharmaceutical industry. A device like this is obviously not going to change the whole industry by itself. However, incremental improvements like this might eventually enable smaller (though not necessarily small) companies to exist alongside Big Pharma.
Today, it might take 10 years and $100 million to create and market a new drug. Since only huge companies can put up such a large initial investment and wait that long to turn a profit, they dominate the industry. However, there must be a turning point at which smaller companies will be willing to enter the market. It might be 5 years and $50 million, or 2 years and $25 million - who knows? The point is, as drug development time and costs decrease, we get incrementally closer to that turning point.
11/26/09
11/20/09
11/20/09
@badhatharry:
11/20/09
11/20/09
11/20/09
11/21/09
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
Also, when you put them in a circle like this, won't that put certain atoms adjacent to each other when they should actually be opposite each other?
10/09/09
I can't make head nor tail of the relationships this is supposed to imply. Why are the rare earth metals at the end of the period for the first two rows? Why do hydrogen and helium point at the transition metals? How does the atomic number change across the diagram?
10/09/09
Umm, we used this bad boy in my chemistry class:
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
10/09/09
Try looking up once in a while stupid bitch.
10/09/09
10/09/09
[emailsfromcrazypeople.com]
08/04/09
To address the some issues raised below, R+D costs are essentially negligible when bringing a drug to market. More money is spent in marketing a drug before it is even approved by the FDA than is spent on R+D. This chip would be only a tiny part of R+D.
Secondly, the analysis of the reaction products is not that hard. You run the product solution into the mass spec and measure the ratio of reaction substrates to reaction product. The only trick is to develop a valve system that controls the delivery of the reactions to the mass spec.
Third, the big use for these devices is their use in sensors that allow a small amount of sample (like blood) to be tested against a large panel of drugs. It could give you a deep view into a patients metabolic state, for example.
08/04/09
08/04/09
08/04/09
"hurry up and wait"... Just curious, do you actually know anything about the FDA approval process for new drugs or are you just echoing what you've heard other say?
08/04/09
08/04/09
08/04/09
08/04/09
...to reduce costs for drug companies, so they can get a new set of gold rims on their bentley golf carts.
08/04/09
08/04/09
08/04/09
08/04/09
Today, it might take 10 years and $100 million to create and market a new drug. Since only huge companies can put up such a large initial investment and wait that long to turn a profit, they dominate the industry. However, there must be a turning point at which smaller companies will be willing to enter the market. It might be 5 years and $50 million, or 2 years and $25 million - who knows? The point is, as drug development time and costs decrease, we get incrementally closer to that turning point.
04/20/09
04/20/09
04/20/09